Livzon Pharmaceutical Group Inc.

Symbol: 000513.SZ

SHZ

40.77

CNY

Market price today

  • 19.2449

    P/E Ratio

  • 0.5004

    PEG Ratio

  • 33.22B

    MRK Cap

  • 0.04%

    DIV Yield

Livzon Pharmaceutical Group Inc. (000513-SZ) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.64%

Operating Profit Margin

0.19%

Net Profit Margin

0.16%

Return on Assets

0.08%

Return on Equity

0.14%

Return on Capital Employed

0.14%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO:Mr. Yanggang Tang
Full-time employees:8933
City:Zhuhai
Address:Headquarters Building
IPO:1993-10-28
CIK:

Livzon Pharmaceutical Group Inc. engages in the research, development, production, and sale of pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People's Republic of China. The company offers Ilaprazole enteric coated tablets for the treatment of duodenal ulcers and reflux esophagitis; Laprazole sodium for injection to treat peptic ulcer hemorrhage; Leuprorelin Acetate Microspheres for injection; Urofollitropin for injection to treat anovulation and sufferers; Perospirone Hydrochloride for the treatment of schizophrenia; Anti-viral Granules to treat upper respiratory tract infection and influenza; and Shenqi Fuzheng Injection for the treatment of weakness and tiredness, lassitude, spontaneous sweating, and vertigo, as well as for the patients of lung and stomach cancer. It also offers diagnostic reagents, such as diagnostic kit for IgM/IgG antibody to coronavirus; nucleic acid test kit for human immunodeficiency virus type 1; antinuclear antibody test kits; interferon-gamma release assays test kits; and rapid test for mycoplasma pneumoniae IgM antibody. In addition, the company provides biochemical drugs, microbiological preparations, biologic products, Chinese drug preparations and pharmaceutical raw materials, and antibiotics. It also exports its products. The company was founded in 1985 and is headquartered in Zhuhai, China.

General Outlook

When we look at how much money they make before expenses, they keep 0.637% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.193%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.162%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.079% return, is a testament to Livzon Pharmaceutical Group Inc.'s adeptness in optimizing resource deployment. Livzon Pharmaceutical Group Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.142%. Furthermore, the proficiency of Livzon Pharmaceutical Group Inc. in capital utilization is underscored by a remarkable 0.140% return on capital employed.

Stock Prices

Livzon Pharmaceutical Group Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $36.93, while its low point bottomed out at $35.9. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Livzon Pharmaceutical Group Inc.'s stock market.

Liquidity Ratios

Analyzing 000513.SZ liquidity ratios reveals its financial health of the firm. The current ratio of 206.22% gauges short-term asset coverage for liabilities. The quick ratio (180.15%) assesses immediate liquidity, while the cash ratio (133.77%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio206.22%
Quick Ratio180.15%
Cash Ratio133.77%

Profitability Ratios

000513.SZ profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 20.29% underscores its earnings before tax deductions. The effective tax rate stands at 19.83%, revealing its tax efficiency. The net income per EBT, 79.80%, and the EBT per EBIT, 105.22%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 19.29%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin20.29%
Effective Tax Rate19.83%
Net Income per EBT79.80%
EBT per EBIT105.22%
EBIT per Revenue19.29%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 2.06, it details the span from stock purchase to revenue. The 2 days it takes to settle debts showcases its creditor relations. Meanwhile, a 1 cash conversion cycle and 323.74% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding180
Days of Inventory Outstanding166
Operating Cycle278.54
Days of Payables Outstanding147
Cash Conversion Cycle132
Receivables Turnover3.24
Payables Turnover2.49
Inventory Turnover2.20
Fixed Asset Turnover2.66
Asset Turnover0.49

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 4.23, and free cash flow per share, 3.34, depict cash generation on a per-share basis. The cash per share value, 12.01, showcases liquidity position. A payout ratio of 0.80 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, 0.32, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share4.23
Free Cash Flow per Share3.34
Cash per Share12.01
Payout Ratio0.80
Operating Cash Flow Sales Ratio0.32
Free Cash Flow to Operating Cash Flow Ratio0.79
Cash Flow Coverage Ratio1.11
Short Term Coverage Ratio1.46
Capital Expenditure Coverage Ratio4.77
Dividend Paid and Capex Coverage Ratio1.64
Dividend Payout Ratio0.05

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 14.15%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.24, we discern the balance between debt and equity financing. The long-term debt to capitalization, 5.59%, and total debt to capitalization, 19.62%, ratios shed light on its capital structure. An interest coverage of 23.06 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio14.15%
Debt Equity Ratio0.24
Long Term Debt to Capitalization5.59%
Total Debt to Capitalization19.62%
Interest Coverage23.06
Cash Flow to Debt Ratio1.11
Company Equity Multiplier1.72

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 13.22, provides a glimpse into top-line earnings distributed across each share. Net income per share, 2.10, reflects the portion of profit attributed to each share. The book value per share, 15.11, represents the net asset value distributed per share, while the tangible book value per share, 15.28, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share13.22
Net Income Per Share2.10
Book Value Per Share15.11
Tangible Book Value Per Share15.28
Shareholders Equity Per Share15.11
Interest Debt Per Share5.52
Capex Per Share-0.88

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -2.78%, indicates top-line expansion, while the gross profit growth, -9.94%, reveals profitability trends. EBIT growth, -18.24%, and operating income growth, -18.24%, offer insights into operational profitability progression. The net income growth, 2.32%, showcases bottom-line expansion, and the EPS growth, 2.94%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth-2.78%
Gross Profit Growth-9.94%
EBIT Growth-18.24%
Operating Income Growth-18.24%
Net Income Growth2.32%
EPS Growth2.94%
EPS Diluted Growth2.94%
Weighted Average Shares Growth-0.63%
Weighted Average Shares Diluted Growth-0.56%
Dividends per Share Growth23.05%
Operating Cash Flow Growth22.42%
Free Cash Flow Growth40.45%
10-Year Revenue Growth per Share141.45%
5-Year Revenue Growth per Share39.14%
3-Year Revenue Growth per Share17.60%
10-Year Operating CF Growth per Share600.63%
5-Year Operating CF Growth per Share168.85%
3-Year Operating CF Growth per Share58.27%
10-Year Net Income Growth per Share263.97%
5-Year Net Income Growth per Share81.27%
3-Year Net Income Growth per Share14.78%
10-Year Shareholders Equity Growth per Share281.32%
5-Year Shareholders Equity Growth per Share32.37%
3-Year Shareholders Equity Growth per Share16.86%
10-Year Dividend per Share Growth per Share650.89%
5-Year Dividend per Share Growth per Share42.41%
3-Year Dividend per Share Growth per Share45.59%
Receivables Growth-14.87%
Inventory Growth0.75%
Asset Growth0.72%
Book Value per Share Growth1.84%
Debt Growth39.17%
R&D Expense Growth-31.78%
SGA Expenses Growth-8.22%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 26,238,993,331.35, captures the company's total value, considering both debt and equity. Income quality, 1.74, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.05, gauges operational efficiency, while the research and development to revenue, 7.93%, highlights investment in innovation. The ratio of intangibles to total assets, 3.35%, indicates the value of non-physical assets, and capex to operating cash flow, -24.17%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value26,238,993,331.35
Income Quality1.74
Sales General and Administrative to Revenue0.05
Research and Development to Revenue7.93%
Intangibles to Total Assets3.35%
Capex to Operating Cash Flow-24.17%
Capex to Revenue-6.68%
Capex to Depreciation-94.70%
Stock-Based Compensation to Revenue0.62%
Graham Number26.74
Return on Tangible Assets8.07%
Graham Net Net5.56
Working Capital9,179,037,244
Tangible Asset Value14,196,990,276
Net Current Asset Value7,257,421,049
Average Receivables3,966,987,780
Average Payables1,312,923,802
Average Inventory2,052,996,365.5
Days Sales Outstanding108
Days Payables Outstanding57
Days of Inventory On Hand153
ROIC7.97%
ROE0.14%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 2.61, and the price to book ratio, 2.61, reflect the market's valuation relative to the company's book value. The price to sales ratio, 2.72, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 10.62, and price to operating cash flows, 9.63, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio2.61
Price to Book Ratio2.61
Price to Sales Ratio2.72
Price Cash Flow Ratio9.63
Price Earnings to Growth Ratio0.50
Enterprise Value Multiple14.94
Price Fair Value2.61
Price to Operating Cash Flow Ratio9.63
Price to Free Cash Flows Ratio10.62
Price to Tangible Book Ratio2.32
Enterprise Value to Sales2.14
Enterprise Value Over EBITDA9.41
EV to Operating Cash Flow7.73
Earnings Yield6.01%
Free Cash Flow Yield7.91%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Livzon Pharmaceutical Group Inc. (000513.SZ) on the SHZ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 19.245 in 2024.

What is the ticker symbol of Livzon Pharmaceutical Group Inc. stock?

The ticker symbol of Livzon Pharmaceutical Group Inc. stock is 000513.SZ.

What is company IPO date?

IPO date of Livzon Pharmaceutical Group Inc. is 1993-10-28.

What is company current share price?

Current share price is 40.770 CNY.

What is stock market cap today?

The market cap of stock today is 33220944771.000.

What is PEG ratio in 2024?

The current 0.500 is 0.500 in 2024.

What is the number of employees in 2024?

In 2024 the company has 8933.